There are similarities and differences. Without question, the issue of transparency on the new substances side is less than it is on the side of existing substances. I would remind members that we have discussed that in the past. The issue is confidential business information with which industry is able to come forward. The onus is on them to provide the government with the data we need. But it is often cloaked with confidential business information that does not apply, or tends to apply less, to substances that are already in commerce, which we will be dealing with through the existing substances side.
In an effort to improve accountability, I'd just point out, a portal has been launched with information on all of these substances, so as the public increases its awareness about these, they will be able to find information about them. If, as we've seen, they're starting to show up in places we don't suspect, there's an opportunity for them to provide us with questions and information that will help us as we move forward.